Translated by TIAN Ran 1,2 , LAM Wai Ching 1,2 , DUAN Yuting 1,2 , BIAN Zhaoxiang 1,2 , ZHANG Chi 3 , SHANG Hongcai 3 , 译
  • 1. School of Chinese Medicine, Hong Kong Baptist University, HongKong 999077, P.R.China;
  • 2. Chinese EQUATOR Centre, HongKong 999077, P.R.China;
  • 3. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R.China;
BIAN Zhaoxiang, Email: bianzxiang@gmail.com
10.7507/1672-2531.202008178
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

草药产品被广泛使用，其成分及质量差异很大，在随机对照试验（randomized controlled trials，RCTs）中也十分常见。笔者基于 22 项 CONSORT 条目清单，对含草药干预措施 RCTs 的报告内容提出推荐条目。经过电话沟通，笔者于加拿大多伦多与 16 位专家进行了专家共识会议。工作组通过了 9 项草药 RCTs 的 CONSORT 清单条目，其中针对草药干预措施的条目 4 阐述最为详尽。这些推荐将会用于改善草药干预措施 RCTs 的报告。

Citation： Translated by TIAN Ran, LAM Wai Ching, DUAN Yuting, BIAN Zhaoxiang, ZHANG Chi, SHANG Hongcai. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Chinese Journal of Evidence-Based Medicine, 2021, 21(1): 97-99. doi: 10.7507/1672-2531.202008178 Copy

Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved

  • Previous Article

    Rational use of oral H1 receptor antagonists in children: a clinical practice guideline protocol